Insights

Strategic merger The merger of BerGenBio with Oncoinvent creates a combined platform focused on alpha radiation-based cancer therapies, offering a unique value proposition that can be pitched to specialized oncology centers and biopharma partners seeking radiopharmaceutical collaboration and accelerated clinical development.

Phase 2 momentum Oncoinvent is actively advancing into Phase 2 trials for Radspherin, with international recruitment and regulatory alignment efforts, presenting opportunities to engage contract research organizations, regional distributors, and key opinion leaders to accelerate site activation and patient enrollment.

Abdominal cancer niche Radspherin targets residual micrometastases in the abdominal cavity with localized alpha radiation, addressing a high-need area post-surgery for ovarian and colorectal cancers, creating a strong case for hospital partnerships, payer discussions, and fellowship programs to drive adoption.

Capital readiness Recent private placement and retail offering funding indicate strong investor interest and potential for further strategic partnerships, licensing, or co-development deals to scale manufacturing, distribution, and global trials.

Technology stack & reach The company’s digital presence and tech stack (WordPress, analytics, e-commerce, and cloud tools) suggests opportunities for digital collaborations, data-sharing agreements, and patient recruitment platforms to enhance trial visibility and stakeholder engagement.

Similar companies to BerGenBio ASA - Merged with Oncoinvent ASA

BerGenBio ASA - Merged with Oncoinvent ASA Tech Stack

BerGenBio ASA - Merged with Oncoinvent ASA uses 8 technology products and services including gstatic.com, WordPress, Shopify, and more. Explore BerGenBio ASA - Merged with Oncoinvent ASA's tech stack below.

Media & News

BerGenBio ASA - Merged with Oncoinvent ASA's Email Address Formats

BerGenBio ASA - Merged with Oncoinvent ASA uses at least 7 email formats:
BerGenBio ASA - Merged with Oncoinvent ASA Email FormatsExamplePercentage
First.Last@bergenbio.comJohn.Doe@bergenbio.com
95%
Last@bergenbio.comDoe@bergenbio.com
3%
First_Last@bergenbio.comJohn_Doe@bergenbio.com
2%
Last@oncoinvent.comDoe@oncoinvent.com
48%
First.Last@oncoinvent.comJohn.Doe@oncoinvent.com
36%
First.Middle.Last@oncoinvent.comJohn.Michael.Doe@oncoinvent.com
15%
FirstL@oncoinvent.comJohnD@oncoinvent.com
1%

Frequently Asked Questions

What is BerGenBio ASA - Merged with Oncoinvent ASA's phone number?

Minus sign iconPlus sign icon
You can contact BerGenBio ASA - Merged with Oncoinvent ASA's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is BerGenBio ASA - Merged with Oncoinvent ASA's official website and social media links?

Minus sign iconPlus sign icon
BerGenBio ASA - Merged with Oncoinvent ASA's official website is oncoinvent.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does BerGenBio ASA - Merged with Oncoinvent ASA generate?

Minus sign iconPlus sign icon
As of October 2026, BerGenBio ASA - Merged with Oncoinvent ASA's annual revenue is estimated to be <$1M.

What is BerGenBio ASA - Merged with Oncoinvent ASA's SIC code and NAICS code?

Minus sign iconPlus sign icon
BerGenBio ASA - Merged with Oncoinvent ASA's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does BerGenBio ASA - Merged with Oncoinvent ASA have currently?

Minus sign iconPlus sign icon
As of October 2026, BerGenBio ASA - Merged with Oncoinvent ASA has approximately 6 employees across 1 continents, including Europe. Key team members include Chief People Officer: D. M., Full Time Senior Researcher, Vp Of Contract Services: T. S. and Director Of Biomarkers And Research: D. M. Explore BerGenBio ASA - Merged with Oncoinvent ASA's employee directory with LeadIQ.

What industry does BerGenBio ASA - Merged with Oncoinvent ASA belong to?

Minus sign iconPlus sign icon
BerGenBio ASA - Merged with Oncoinvent ASA operates in the Biotechnology Research industry.

What technology does BerGenBio ASA - Merged with Oncoinvent ASA use?

Minus sign iconPlus sign icon
BerGenBio ASA - Merged with Oncoinvent ASA's tech stack includes gstatic.com, WordPress, Shopify, Amazon Simple Email Service, Microsoft 365, X-XSS-Protection, Google Analytics and Supsystic.

What is BerGenBio ASA - Merged with Oncoinvent ASA's email format?

Minus sign iconPlus sign icon
BerGenBio ASA - Merged with Oncoinvent ASA's email format typically follows the pattern of First.Last@bergenbio.com. Find more BerGenBio ASA - Merged with Oncoinvent ASA email formats with LeadIQ.

How much funding has BerGenBio ASA - Merged with Oncoinvent ASA raised to date?

Minus sign iconPlus sign icon
As of October 2026, BerGenBio ASA - Merged with Oncoinvent ASA has raised $183M in funding. The last funding round occurred on Nov 30, 2023 for $23M.

When was BerGenBio ASA - Merged with Oncoinvent ASA founded?

Minus sign iconPlus sign icon
BerGenBio ASA - Merged with Oncoinvent ASA was founded in 2008.
BerGenBio ASA - Merged with Oncoinvent ASA logo

BerGenBio ASA - Merged with Oncoinvent ASA

Biotechnology ResearchVestland, Norway2-10 Employees

On 29 October 2025, BerGenBio ASA merged with Oncoinvent ASA, and the combined entity operates under the name Oncoinvent ASA. The company is in the biotechnology research industry and is based in Bergen, Norway (address: 91 Jonas Lies Vei Bergen, Vestland 5009 Norway), with a small workforce of 2 to 10 employees. Oncoinvent ASA is developing Radspherin, a receptor-independent alpha radiation therapy for cancers in the abdominal cavity. The company has begun recruitment for phase 2 studies in Norway and internationally, with preliminary studies reporting positive findings. BerGenBio’s LinkedIn page is being maintained only as a historical archive following the merger.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2008
Employees
2-10

Section iconFunding & Financials

  • $183M

    BerGenBio ASA - Merged with Oncoinvent ASA has raised a total of $183M of funding over 10 rounds. Their latest funding round was raised on Nov 30, 2023 in the amount of $23M as a Post IPO Debt.

  • <$1M

    BerGenBio ASA - Merged with Oncoinvent ASA's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.